These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The company said the safety profile remained consistent with earlier studies and was considered manageable
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
The regulatory decision follows promising results from RIVER-81
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
